Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Levocarnitine Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.67 |
| ▸ | HSP90AA1 known ✓ | P07900 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.97 |
| ▸ | RECQL | P46063 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.67 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.66 |
| ▸ | TSHR | P16473 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | THPO | P40225 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionyl-Carnitine SCHEMBL1358526 | 1.00 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Levocarnitine Propionate SCHEMBL464940 | 0.98 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL156850 | 0.98 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL994714 | 0.98 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Levocarnitine Propionate SCHEMBL3005249 | 0.97 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL19617435 | 0.93 | MEN1 (0.90) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL583770 | 0.92 | MEN1 (0.88) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL3637406 | 0.91 | MEN1 (0.80) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Levocarnitine Propionate SCHEMBL3637409 | 0.91 | MEN1 (0.80) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL527837 | 0.91 | MEN1 (0.85) | MEN1KMT2ACYP2C19RECQLCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425444-A1 | PROCESS FOR PRODUCING CRYSTALLINE L-CARNITINE | HUBEI XUJIE PHARMACEUTICAL CO., LTD (CN) | 2024-12-26 | — | — | US | claimed |
| US-20240228429-A1 | PROCESS FOR PRODUCING L-CARNITINE | HUBEI XUJIE PHARMACEUTICAL CO., LTD (CN) | 2024-07-11 | — | — | US | claimed |
| US-20240217920-A1 | PROCESS FOR PRODUCING L-CARNITINE | HUBEI XUJIE PHARMACEUTICAL CO., LTD (CN) | 2024-07-04 | — | — | US | claimed |
| CN-117617501-A | Extraction process of lime peel | 江西省林业科学院 | 2024-03-01 | — | — | CN | claimed |
| WO-2023185709-A1 | MARKER COMBINATION FOR DIAGNOSING ADVANCED COLORECTAL TUMOR, AND APPLICATION THEREOF | 武汉迈特维尔医学科技有限公司 | 2023-10-05 | — | — | WO | claimed |
| CN-114924073-A | Colorectal progression stage tumor diagnosis marker combination and application thereof | 武汉迈特维尔生物科技有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-113917034-A | Biomarker combination for evaluating Alzheimer's disease and application and kit thereof | 北京豪思生物科技有限公司 | 2022-01-11 | — | — | CN | claimed |
| CN-111960959-A | Preparation method of glycine propionyl L-carnitine hydrochloride moisture-proof particles | 辽宁科硕营养科技股份有限公司 | 2020-11-20 | — | — | CN | claimed |
| JP-4708655-B2 | — | — | 2011-06-22 | — | — | JP | claimed |
| CN-100425590-C | Propionyl-L-carnitine inner salt synthesis method | SHANDONG QIDU PHARMACEUTICAL C (CN) | 2008-10-15 | — | — | CN | claimed |
| CN-1290821-C | propionyl-L-carnitine synthesis process | SHANDONG QIDU PHARMACEUTICAL C (CN) | 2006-12-20 | — | — | CN | claimed |
| CN-1865231-A | Propionyl-L-carnitine inner salt synthesis method | SHANDONG QIDU PHARMACEUTICAL C (CN) | 2006-11-22 | — | — | CN | claimed |
| EP-1257524-B1 | A PROCESS FOR THE PREPARATION OF SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINE WITH MUCIC ACID | SIGMA TAU IND FARMACEUTI (IT) | 2005-11-02 | — | — | EP | claimed |
| CN-1651402-A | propionyl-L-carnitine synthesis process and detection method of related substances and content | SHANDONG QIDU PHARMACEUTICAL C (CN) | 2005-08-10 | — | — | CN | claimed |
| US-6693215-B2 | TREATING CARNITINE CHLORIDE WITH AN ION EXCHANGER TO FORM AN INNER SALT IN AQUEOUS SOLUTION BEFORE REACTING WITH MUCIC ACID | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-02-17 | — | — | US | claimed |
| US-20030130539-A1 | Process for the preparation of salts of l-carnitine and alkanoyl l-carnitine with mucic acid | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-07-10 | — | — | US | claimed |
| EP-1257524-A1 | A PROCESS FOR THE PREPARATION OF SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINE WITH MUCIC ACID | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2002-11-20 | — | — | EP | claimed |
| WO-2001058850-A1 | A PROCESS FOR THE PREPARATION OF SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINE WITH MUCIC ACID | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-08-16 | — | — | WO | claimed |
| US-6217898-B1 | ANTICHOLESTEROL AGENTS | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2001-04-17 | — | — | US | claimed |
| WO-2024263444-A2 | PROCESS FOR PRODUCING CRYSTALLINE L-CARNITINE | CARNITECH LLC (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240425444-A1 | PROCESS FOR PRODUCING CRYSTALLINE L-CARNITINE | HUBEI XUJIE PHARMACEUTICAL CO., LTD (CN) | 2024-12-26 | — | — | US | disclosed |
| US-20240228429-A1 | PROCESS FOR PRODUCING L-CARNITINE | HUBEI XUJIE PHARMACEUTICAL CO., LTD (CN) | 2024-07-11 | — | — | US | disclosed |
| WO-2024145205-A1 | AN IMPROVED PROCESS FOR PRODUCING L-CARNITINE | CARNITECH LLC (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240217920-A1 | PROCESS FOR PRODUCING L-CARNITINE | HUBEI XUJIE PHARMACEUTICAL CO., LTD (CN) | 2024-07-04 | — | — | US | disclosed |
| CN-117617501-A | Extraction process of lime peel | 江西省林业科学院 | 2024-03-01 | — | — | CN | disclosed |
| CN-114924073-B | Tumor diagnosis marker combination in colorectal progression stage and application thereof | 武汉迈特维尔医学科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-114924073-B | Tumor diagnosis marker combination in colorectal progression stage and application thereof | 武汉迈特维尔医学科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023185709-A1 | MARKER COMBINATION FOR DIAGNOSING ADVANCED COLORECTAL TUMOR, AND APPLICATION THEREOF | 武汉迈特维尔医学科技有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023185709-A1 | MARKER COMBINATION FOR DIAGNOSING ADVANCED COLORECTAL TUMOR, AND APPLICATION THEREOF | 武汉迈特维尔医学科技有限公司 | 2023-10-05 | — | — | WO | disclosed |
| CN-114924073-A | Colorectal progression stage tumor diagnosis marker combination and application thereof | 武汉迈特维尔生物科技有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114924073-A | Colorectal progression stage tumor diagnosis marker combination and application thereof | 武汉迈特维尔生物科技有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-113917034-A | Biomarker combination for evaluating Alzheimer's disease and application and kit thereof | 北京豪思生物科技有限公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-111960959-A | Preparation method of glycine propionyl L-carnitine hydrochloride moisture-proof particles | 辽宁科硕营养科技股份有限公司 | 2020-11-20 | — | — | CN | disclosed |
| CN-107325013-B | A method of synthesis glycine propionyl levo-carnitine hydrochloride | 辽宁科硕营养科技股份有限公司 | 2019-04-12 | — | — | CN | disclosed |
| US-20190047940-A1 | SALTS OF CARNITINE DERIVATIVES AND METHODS OF PRODUCTION | THERMOLIFE INTERNATIONAL, LLC | 2019-02-14 | — | — | US | disclosed |
| US-10100003-B2 | Salts of carnitine derivatives and methods of production | THERMOLIFE INTERNATIONAL, LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20170158612-A1 | SALTS OF CARNITINE DERIVATIVES AND METHODS OF PRODUCTION | THERMOLIFE INTERNATIONAL, LLC | 2017-06-08 | — | — | US | disclosed |
| US-9573883-B2 | Salts of carnitine derivatives and methods of production | THERMOLIFE INTERNATIONAL, LLC (US) | 2017-02-21 | — | — | US | disclosed |
| WO-2016099465-A1 | SALTS OF CARNITINE DERIVATIVES AND METHODS OF PRODUCTION | THERMOLIFE INTERNATIONAL, LLC (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2015095236-A1 | SALTS OF CARNITINE DERIVATIVES AND METHODS OF PRODUCTION | KRAMER RONALD (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150166466-A1 | SALTS OF CARNITINE DERIVATIVES AND METHODS OF PRODUCTION | THERMOLIFE INTERNATIONAL, LLC | 2015-06-18 | — | — | US | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |
| CN-103070833-A | Freeze-dried powder injection of propionyl-L-carnitine hydrochloride and preparation method of freeze-dried powder injection | BEIJING FUKANGREN BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2013-05-01 | — | — | CN | disclosed |
| CN-103070833-A | Freeze-dried powder injection of propionyl-L-carnitine hydrochloride and preparation method of freeze-dried powder injection | BEIJING FUKANGREN BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2013-05-01 | — | — | CN | disclosed |
| EP-2508179-A1 | Use of L-Carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function | Lonza Ltd. (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8067468-B2 | L-carnitine and alkanoyl L-carnitine phytates and process for preparing the same | SCIAN LABORATORIES, LLC | 2011-11-29 | — | — | US | disclosed |
| EP-2299994-A1 | L-CARNITINE AND ALKANOYL L-CARNITINE PHYTATES AND PROCESS FOR PREPARING THE SAME | Scian Laboratories, Llc (US) | 2011-03-30 | — | — | EP | disclosed |
| US-7858820-B2 | Solid compositions suitable for oral administration containing non-hygroscopic salts of L-carnitine and the alkanoyl L-carnitines with taurine chloride and glycine chloride | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-12-28 | — | — | US | disclosed |
| US-7854939-B2 | Gel useful for the delivery of cosmetic active ingredients | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-12-21 | — | — | US | disclosed |
| US-20100317890-A1 | L-carnitine and alkanoyl L-carnitine phytates and process for preparing the same | SCIAN LABORATORIES, LLC (US) | 2010-12-16 | — | — | US | disclosed |
| EP-2152225-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2010-02-17 | — | — | EP | disclosed |
| WO-2010005465-A1 | L-CARNITINE AND ALKANOYL L-CARNITINE PHYTATES AND PROCESS FOR PREPARING THE SAME | SCIAN LABORATORIES, LLC (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20090312421-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2009-12-17 | — | — | US | disclosed |
| EP-1729732-B1 | ANIONIC HYDROGEL MATRICES WITH PH DEPENDENT MODIFIED RELEASE AS DRUG CARRIERS | SIGMA TAU IND FARMACEUTI (IT) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008138393-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-11-20 | — | — | WO | disclosed |
| US-20080279900-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2008-11-13 | — | — | US | disclosed |
| CN-100425590-C | Propionyl-L-carnitine inner salt synthesis method | SHANDONG QIDU PHARMACEUTICAL C (CN) | 2008-10-15 | — | — | CN | disclosed |
| CN-100425590-C | Propionyl-L-carnitine inner salt synthesis method | SHANDONG QIDU PHARMACEUTICAL C (CN) | 2008-10-15 | — | — | CN | disclosed |
| CN-100359326-C | Method for investigating propylene L-relavent matter and content | SHANDONG QIDU PHARMACEUTICAL C (CN) | 2008-01-02 | — | — | CN | disclosed |
| US-20070166383-A1 | Anionic hydrogel matrices with ph dependent modified release as drug carriers | SIGMA-TAU INDUSTIRE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-07-19 | — | — | US | disclosed |
| CN-1290821-C | propionyl-L-carnitine synthesis process | SHANDONG QIDU PHARMACEUTICAL C (CN) | 2006-12-20 | — | — | CN | disclosed |
| EP-1729732-A1 | ANIONIC HYRDOGEL MATRICES WITH PH DEPENDENT MODIFIED RELEASE AS DRUG CARRIERS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2006-12-13 | — | — | EP | disclosed |
| CN-1869682-A | Method for investigating propylene L-relavent matter and content | SHANDONG QIDU PHARMACEUTICAL C (CN) | 2006-11-29 | — | — | CN | disclosed |
| CN-1865231-A | Propionyl-L-carnitine inner salt synthesis method | SHANDONG QIDU PHARMACEUTICAL C (CN) | 2006-11-22 | — | — | CN | disclosed |
| EP-1330428-B1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION CONTAINING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND THE ALKANOYL L-CARNITINES WITH TAURINE CHLORIDE | SIGMA TAU IND FARMACEUTI (IT) | 2005-12-14 | — | — | EP | disclosed |
| EP-1257524-B1 | A PROCESS FOR THE PREPARATION OF SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINE WITH MUCIC ACID | SIGMA TAU IND FARMACEUTI (IT) | 2005-11-02 | — | — | EP | disclosed |
| US-20050232911-A1 | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid | SCHREIBER BRIAN D | 2005-10-20 | — | — | US | disclosed |
| WO-2005094792-A1 | ANIONIC HYDROGEL MATRICES WITH PH DEPENDENT MODIFIED RELEASE AS DRUG CARRIERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2005-10-13 | — | — | WO | disclosed |
| CN-1651402-A | propionyl-L-carnitine synthesis process and detection method of related substances and content | SHANDONG QIDU PHARMACEUTICAL C (CN) | 2005-08-10 | — | — | CN | disclosed |
| EP-1202956-B1 | THERAPEUTICALLY AND/OR NUTRITIONALLY ENHANCED DERIVATIVES OF ACTIVE INGREDIENTS AND ORALLY ADMINISTRABLE COMPOSITIONS CONTAINING SAME | SIGMA TAU IND FARMACEUTI (IT) | 2004-05-19 | — | — | EP | disclosed |
| US-6703042-B1 | STABLE, NON-HYGROSCOPIC; NUTRITIONAL SUPPLEMENTS | SIGMA-TAU INDUSTRIES FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-03-09 | — | — | US | disclosed |
| US-6693215-B2 | TREATING CARNITINE CHLORIDE WITH AN ION EXCHANGER TO FORM AN INNER SALT IN AQUEOUS SOLUTION BEFORE REACTING WITH MUCIC ACID | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-02-17 | — | — | US | disclosed |
| US-20040024061-A1 | Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride | ALFASIGMA S.P.A. (IT) | 2004-02-05 | — | — | US | disclosed |
| EP-1093451-B1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION CONTAINING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINES | SIGMA TAU IND FARMACEUTI (IT) | 2003-09-03 | — | — | EP | disclosed |
| EP-1330428-A1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION CONTAINING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND THE ALKANOYL L-CARNITINES WITH TAURINE CHLORIDE AND GLYCINE CHLORIDE | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2003-07-30 | — | — | EP | disclosed |
| US-20030130539-A1 | Process for the preparation of salts of l-carnitine and alkanoyl l-carnitine with mucic acid | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-07-10 | — | — | US | disclosed |
| US-6465515-B2 | SALT WITH PAMOIC ACID, USED IN TREATMENT OF MYOCARDIAL ISCHEMIA, ANGINA PECTORIS, HEART FAILURE AND ARRHYTHMIAS; MUSCULAR ASTHENIA AND CRAMPS; AS FOOD SUPPLEMENT, DIETETIC | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-10-15 | — | — | US | disclosed |
| WO-2002036543-A1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION CONTAINING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND THE ALKANOYL L-CARNITINES WITH TAURINE CHLORIDE AND GLYCINE CHLORIDE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-05-10 | — | — | WO | disclosed |
| EP-1202956-A1 | THERAPEUTICALLY AND/OR NUTRITIONALLY ENHANCED DERIVATIVES OF ACTIVE INGREDIENTS AND ORALLY ADMINISTRABLE COMPOSITIONS CONTAINING SAME | Biosalts S.r.l. (IT) | 2002-05-08 | — | — | EP | disclosed |
| US-20010009923-A1 | Solid compositions suitable for oral administration containing non-hygroscopic salts of L-carnitine and alkanoyl L-carnitines | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-07-26 | — | — | US | disclosed |
| EP-1093451-A1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION CONTAINING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2001-04-25 | — | — | EP | disclosed |
| WO-2000073258-A1 | THERAPEUTICALLY AND/OR NUTRITIONALLY ENHANCED DERIVATIVES OF ACTIVE INGREDIENTS AND ORALLY ADMINISTRABLE COMPOSITIONS CONTAINING SAME | BIOSALTS S.R.L. (IT) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000001662-A1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION CONTAINING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-01-13 | — | — | WO | disclosed |
| US-5543556-A | NERVOUS SYSTEM DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1996-08-06 | — | — | US | disclosed |
| US-5534549-A | Easters of acyl L-carnitines with gamma-hydroxybutyric acid and pharmaceutical compositions containing them for inhibiting neuronal degeneration and for the treatment of coma | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1996-07-09 | — | — | US | disclosed |
| EP-0514357-B1 | Use of esters of acyl L-carnitines with gamma-hydroxybutyric acid for producing pharmaceutical compositions for the treatment of hepatopathies | SIGMA TAU IND FARMACEUTI (IT) | 1996-01-10 | — | — | EP | disclosed |
| EP-0514359-B1 | Alkanoyl L-carnitine amides with aminoacids and pharmaceutical compositions containing same, for promoting regeneration of the nervous tissue, inhibiting neuronal degeneration, enhancing the processes of learning and memory, and for the treatment of coma | SIGMA TAU IND FARMACEUTI (IT) | 1995-09-13 | — | — | EP | disclosed |
| EP-0442850-B1 | Esters of acyl L-carnitines with gamma-hydroxybutyric acid and pharmaceutical compositions containing them for inhibiting neuronal degeneration and for the treatment of coma | SIGMA TAU IND FARMACEUTI (IT) | 1994-07-27 | — | — | EP | disclosed |
| EP-0443996-B1 | Esters of (R)(-)-carnitine and acyl (R)(-)-carnitines with beta-hydroxybutyric acid and pharmaceutical compositions containing them for inhibiting neuronal degeneration, liver proteolysis and for the treatment of coma | SIGMA TAU IND FARMACEUTI (IT) | 1994-06-22 | — | — | EP | disclosed |
| US-5270472-A | Alkanoyl L-carnitine amides with aminoacids and pharmaceutical compositions containing same for promoting regeneration of the nervous tissue, inhibiting neuronal degeneration, enhancing the process of learning and memory and for the treatment of coma | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1993-12-14 | — | — | US | disclosed |
| US-5246967-A | USE OF ESTERS OF ACYL L-CARNITINES WITH GAMMA-HYDROXYBUTYRIC ACID FOR PRODUCING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATOPATHIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1993-09-21 | — | — | US | disclosed |
| EP-0514359-A2 | Alkanoyl L-carnitine amides with aminoacids and pharmaceutical compositions containing same, for promoting regeneration of the nervous tissue, inhibiting neuronal degeneration, enhancing the processes of learning and memory, and for the treatment of coma | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-11-19 | — | — | EP | disclosed |
| EP-0514357-A1 | Use of esters of acyl L-carnitines with gamma-hydroxybutyric acid for producing pharmaceutical compositions for the treatment of hepatopathies | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-11-19 | — | — | EP | disclosed |
| EP-0443996-A1 | Esters of (R)(-)-carnitine and acyl (R)(-)-carnitines with beta-hydroxybutyric acid and pharmaceutical compositions containing them for inhibiting neuronal degeneration, liver proteolysis and for the treatment of coma | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1991-08-28 | — | — | EP | disclosed |
| EP-0442850-A1 | Esters of acyl L-carnitines with gamma-hydroxybutyric acid and pharmaceutical compositions containing them for inhibiting neuronal degeneration and for the treatment of coma | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1991-08-21 | — | — | EP | disclosed |
| EP-0150688-B1 | SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINES AND PROCESS FOR PREPARING SAME | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1987-04-22 | — | — | EP | disclosed |
| US-4602039-A | HYDROPHOPIC;BIOLOGICAL INJECTIONS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1986-07-22 | — | — | US | disclosed |
| EP-0150688-A1 | Salts of L-carnitine and alkanoyl L-carnitines and process for preparing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1985-08-07 | — | — | EP | disclosed |
| EP-0150688-A1 | Salts of L-carnitine and alkanoyl L-carnitines and process for preparing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217920-A1 | PROCESS FOR PRODUCING L-CARNITINE | CRAT, SLC25A20, CPT2 | HRH1 2475/4885HSP90AA1 2421/4885MEN1 3564/4885 |
| US-20240228429-A1 | PROCESS FOR PRODUCING L-CARNITINE | CRAT, CPT1B, SLC25A20 | HRH1 4534/4885HSP90AA1 4441/4885MEN1 1910/4885 |
| US-20170158612-A1 | SALTS OF CARNITINE DERIVATIVES AND METHODS OF PRODUCTION | CRAT, SLC25A20, CPT1A | HRH1 4767/4885HSP90AA1 2679/4885MEN1 3034/4885 |
| US-20040024061-A1 | Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride | SLC25A20, SLC6A6, CPT1B | HRH1 1173/4885HSP90AA1 3137/4885MEN1 3090/4885 |
| US-20100317890-A1 | L-carnitine and alkanoyl L-carnitine phytates and process for preparing the same | CPT1A, CPT1B, SLC25A20 | HRH1 1019/4885HSP90AA1 4722/4885MEN1 330/4885 |
| US-20190047940-A1 | SALTS OF CARNITINE DERIVATIVES AND METHODS OF PRODUCTION | CRAT, SLC25A20, CPT1A | HRH1 4767/4885HSP90AA1 2679/4885MEN1 3034/4885 |
| US-20030130539-A1 | Process for the preparation of salts of l-carnitine and alkanoyl l-carnitine with mucic acid | CRAT, SLC25A20, MUC1 | HRH1 1391/4885HSP90AA1 4581/4885MEN1 603/4885 |
| US-10100003-B2 | Salts of carnitine derivatives and methods of production | CRAT, SLC25A20, CPT1A | HRH1 4767/4885HSP90AA1 2679/4885MEN1 3034/4885 |
| US-20010009923-A1 | Solid compositions suitable for oral administration containing non-hygroscopic salts of L-carnitine and alkanoyl L-carnitines | SLC25A20, CPT1B, CPT2 | HRH1 1275/4885HSP90AA1 2353/4885MEN1 1394/4885 |
| US-20080279900-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SLC25A20, CRAT, CUTA | HRH1 3611/4885HSP90AA1 1657/4885MEN1 3124/4885 |
| US-20090312421-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SLC25A20, CRAT, UGCG | HRH1 3743/4885HSP90AA1 1835/4885MEN1 3282/4885 |
| US-20150166466-A1 | SALTS OF CARNITINE DERIVATIVES AND METHODS OF PRODUCTION | CRAT, SLC25A20, CPT1A | HRH1 4767/4885HSP90AA1 2679/4885MEN1 3034/4885 |
| US-20240425444-A1 | PROCESS FOR PRODUCING CRYSTALLINE L-CARNITINE | CPT1A, CRAT, CPT2 | HRH1 3014/4885HSP90AA1 2140/4885MEN1 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.